Bristol-Myers Squibb Company Ce
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELG-RI research report →
About the company
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
- CEO
- Christopher S. Boerner
- IPO
- 2019
- Employees
- 34,100
- HQ
- Princeton, NJ, US
Price Chart
- Market Cap
- $181.74M
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
- Gross Margin
- 96.16%
- Op Margin
- 33.97%
- Net Margin
- 26.48%
- ROE
- 61.86%
- ROIC
- 13.62%
- Revenue
- $15.28B · 17.52%
- Net Income
- $4.05B · 37.62%
- EPS
- $5.51 · 46.15%
- Op Income
- $5.19B
- FCF YoY
- -2.54%
- 52W High
- $0.12
- 52W Low
- $0.09
- 50D MA
- $0.08
- 200D MA
- $0.08
- Beta
- -0.51
- Avg Volume
- 39.73K
Get TickerSpark's AI analysis on CELG-RI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 20, 19 | VESSEY RUPERT | other | 24,209 |
| Nov 20, 19 | VESSEY RUPERT | other | 13,906 |
| Nov 20, 19 | VESSEY RUPERT | other | 8,634 |
| Nov 20, 19 | VESSEY RUPERT | sell | 18,257 |
| Nov 20, 19 | VESSEY RUPERT | sell | 18,257 |
| Nov 20, 19 | VESSEY RUPERT | sell | 613 |
| Nov 20, 19 | VESSEY RUPERT | sell | 26,308 |
| Nov 20, 19 | VESSEY RUPERT | sell | 3,125 |
| Nov 20, 19 | VESSEY RUPERT | sell | 12,906 |
| Nov 20, 19 | VESSEY RUPERT | sell | 11,384 |
Our CELG-RI coverage
Recent articles, reports, and earnings notes.
No research on CELG-RI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELG-RI report →Similar companies
Peers in the same neighborhood.